Tag: Phosphoinositide 3-kinase inhibitor

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Phosphoinositide 3-kinase inhibitor

FDA's tighter scrutiny on drug class leads TG Therapeutics to pull out of cancer - MedCity News

Added to Collection on: 2022-04-18 23:15:34

Tags for this article:

Medicine
Health sciences
Clinical medicine
Food and Drug Administration
Antineoplastic drugs
Orphan drugs
Breakthrough therapy
Drug discovery
Phosphoinositide 3-kinase inhibitor
Idelalisib
Accelerated approval
Duvelisib
TG THERAPEUTICS
TG
Michael Weiss

Click the tags to see associated articles and topics

View Article Details
TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024

Added to Collection on: 2022-12-15 19:19:10

Tags for this article:

Health
Breakthrough therapy
Monoclonal antibodies
Genentech
Ocrelizumab
Drugs
Medicine
Phosphoinositide 3-kinase inhibitor
CD20
Food and Drug Administration
Umbralisib
ublituximab

Click the tags to see associated articles and topics

View Article Details
Roche's inavolisib combination reduces the risk of disease progression by 57% in ... - Yahoo Finance

Added to Collection on: 2023-12-08 22:22:09

Tags for this article:

Amides
Specialty drugs
Aminopyridines
Breakthrough therapy
Protein kinase inhibitors
Palbociclib
Phosphoinositide 3-kinase inhibitor
Alpelisib
Fulvestrant
Breast cancer
Triple-negative breast cancer
PI3K/AKT/mTOR pathway
F. Hoffmann-La Roche
San Antonio
Roche Group

Click the tags to see associated articles and topics

View Article Details
Inavolisib Plus Palbociclib and Fulvestrant Improves PFS in PIK3CA-Mutated HR+ Breast Cancer

Added to Collection on: 2023-12-08 18:14:54

Tags for this article:

Aminopyridines
Protein kinase inhibitors
Breakthrough therapy
Amides
Palbociclib
Fulvestrant
Genentech
Breast cancer
HER2
Inavolisib
Buparlisib
Phosphoinositide 3-kinase inhibitor

Click the tags to see associated articles and topics

View Article Details
2023-12-08 | OTCQX:RHHBY | Press Release | Roche Holdings ADR - Stockhouse

Added to Collection on: 2023-12-08 17:07:09

Tags for this article:

Breast cancer
Aminopyridines
Amides
Lactams
Palbociclib
Phosphoinositide 3-kinase inhibitor
Fulvestrant
Inavolisib
P110α
HER2
Genentech
Metastatic breast cancer

Click the tags to see associated articles and topics

View Article Details
AstraZeneca notes positive trial results for Calquence treatment - Shares Magazine

Added to Collection on: 2024-05-02 15:09:46

Tags for this article:

Antineoplastic drugs
Orphan drugs
Non-Hodgkin lymphoma
Lymphoma
Mantle cell lymphoma
Chemoimmunotherapy
Bendamustine
Hodgkin lymphoma
Acalabrutinib
Rituximab
Chemotherapy regimen
Phosphoinositide 3-kinase inhibitor
AstraZeneca plc

Click the tags to see associated articles and topics

View Article Details
FDA grants Breakthrough Therapy Designation to Roche's - GlobeNewswire

Added to Collection on: 2024-05-21 17:01:56

Tags for this article:

Amides
Aminopyridines
Breast cancer
Antineoplastic drugs
Specialty drugs
Inavolisib
Phosphoinositide 3-kinase inhibitor
Alpelisib
Palbociclib
Fulvestrant
Triple-negative breast cancer
Trastuzumab
Roche Group
u.s. food and drug administration

Click the tags to see associated articles and topics

View Article Details
Roche's PI3K inhibitor secures breakthrough status in breast cancer

Added to Collection on: 2024-05-21 16:15:12

Tags for this article:

Amides
Aminopyridines
Specialty drugs
Phosphoinositide 3-kinase inhibitor
Targeted therapy
Antiestrogens
Palbociclib
Inavolisib
Breast cancer
Fulvestrant
Novartis
P110α

Click the tags to see associated articles and topics

View Article Details
Top ten late-breaking data to look for at ASCO 2024 - Pharmaceutical Technology

Added to Collection on: 2024-05-31 21:10:25

Tags for this article:

Antineoplastic drugs
Orphan drugs
Lung cancer
Piperazines
Fluoroarenes
Amgen
Sotorasib
Non-small-cell lung cancer
Adagrasib
Phosphoinositide 3-kinase inhibitor
Small-cell carcinoma
Melanoma
Shutterstock

Click the tags to see associated articles and topics

View Article Details
Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL

Added to Collection on: 2024-08-19 14:35:35

Tags for this article:

Orphan drugs
Antineoplastic drugs
Chronic lymphocytic leukemia
Ibrutinib
Phosphoinositide 3-kinase inhibitor
Venetoclax
Obinutuzumab
Zanubrutinib
Acalabrutinib
Rituximab
Targeted therapy
Bendamustine

Click the tags to see associated articles and topics

View Article Details